Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma

被引：0
|
作者：
Colomba, E. [1 ]
Alexandre, J. [2 ]
Le Teuff, G. [3 ]
Coupez, D. [4 ]
Genestie, C. [5 ]
Ray-Coquard, I. L. [6 ]
Brachet, P. E. [7 ]
Sajous, C. [8 ]
De Percin, S. [9 ]
Fabbro, M. [10 ]
Delanoy, N. [11 ]
Joly, F. [12 ]
Pautier, P. [13 ]
Frenel, J-S. [14 ]
Leary, A. [15 ]
机构：
[1] Inst Gustave Roussy, Med Oncol Dept, Villejuif, France
[2] Hop Cochin Site Port Royal, AP HP, Oncol, Paris, France
[3] Inst Gustave Roussy, Dept Biostatist, Villejuif, France
[4] CHU Nantes Hotel Dieu, Oncol, Nantes, France
[5] Inst Gustave Roussy, Pathol, Villejuif, France
[6] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[7] Ctr Francois Baclesse, Med Oncol Dept, Caen, France
[8] Inst Cancerol Hosp Civils Lyon IC HCL, Med Oncol Dept, Lyon, France
[9] Hop Univ Paris Ctr Med Oncol, Hop Cochin, Paris, France
[10] Inst Canc Montpellier, Dept Med Oncol, Montpellier, France
[11] Hop European George Pompidou, Dept Med Oncol, Paris, France
[12] Ctr Francois Baclesse, Med Oncol, Caen, France
[13] Inst Gustave Roussy, Dept Med, Villejuif, France
[14] ICO Inst Cancerol IOuest Rene Gauducheau, Dept Med Oncol, Saint Herblain, France
[15] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
801P
引用
收藏
页码：S763 / S763
页数：1
相关论文
共 50 条
  • [41] EU Commission approves dostarlimab plus chemotherapy as first-line immuno-oncology therapy for primary advanced/recurrent MMR/MSI-H endometrial cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (1-2)
  • [42] Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
    Zhu, Chen
    Han, Gang
    Wu, Bin
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [43] Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
    Chen Zhu
    Gang Han
    Bin Wu
    BMC Health Services Research, 23 (1)
  • [44] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
  • [45] Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma
    Liu, Guo-Ying
    Li, Wang-Zhong
    Peng, Kang-Qiang
    Lv, Xing
    Ke, Liang-Ru
    Wu, Yi-Shan
    Wang, De-Ling
    Liang, Hu
    Liu, Kui-Yuan
    Lv, Shu-Hui
    Guo, Xiang
    Xiang, Yan-Qun
    Xia, Wei-Xiong
    CANCER MEDICINE, 2020, 9 (03): : 920 - 930
  • [46] Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
    Minato, Akinori
    Ohno, Daichi
    Murooka, Kazuki
    Okumura, Yutaka
    Takaba, Tomohisa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Harada, Kenichi
    Fujimoto, Naohiro
    IN VIVO, 2024, 38 (04): : 1927 - 1934
  • [47] The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males
    Ishikubo, T
    Nishimura, Y
    Yamaguchi, K
    Khansuwan, U
    Arai, Y
    Kobayashi, T
    Ohkura, Y
    Hashiguchi, Y
    Tanaka, Y
    Akagi, K
    CANCER LETTERS, 2004, 216 (01) : 55 - 62
  • [48] Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.
    Diaz, Luis A.
    Marabelle, Aurelien
    Delord, Jean-Pierre
    Shapira-Frommer, Ronnie
    Geva, Ravit
    Peled, Nir
    Kim, Tae Won
    Andre, Thierry
    Van Cutsenn, Eric
    Guimbaud, Rosine
    Jaeger, Dirk
    Elez, Elena
    Yoshino, Takayuki
    Joe, Andrew K.
    Lam, Baohoang
    Gause, Christine K.
    Pruitt, Scott Knowles
    Kang, S. Peter
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] THE HUMANISTIC BURDEN OF MICROSATELLITE INSTABILITY-HIGH (MSI-H) COLORECTAL CANCER (CRC) AND METASTATIC CRC (MCRC) PATIENTS TREATED WITH SUBSEQUENT LINE THERAPY: A SYSTEMATIC REVIEW
    Kohn, C. G.
    Nguyen, E.
    Miller, J. D.
    Nwokeji, E.
    Laurie, M.
    Kamble
    Khan, T.
    Masood, A.
    Korytowsky, B.
    VALUE IN HEALTH, 2017, 20 (09) : A454 - A454
  • [50] Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability high (MSI-H) tumors.
    Segal, Neil Howard
    Wainberg, Zev A.
    Overman, Michael J.
    Ascierto, Paolo Antonio
    Arkenau, Hendrik-Tobias
    Butler, Marcus O.
    Eder, Joseph Paul
    Keilholz, Ulrich
    Kim, Dong-Wan
    Cunningham, David
    Khleif, Samir N.
    Doucet, Ludovic
    Lee, Jong-Seok
    Nemunaitis, John J.
    Vaishampayan, Ulka N.
    Weiss, Jared
    Gao, Chen
    Abdullah, Shaad Essa
    Hollebecque, Antoine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345